GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, today announced the publication of a peer ...

Oncology, and Biosecurity Amid Strategic Program Developments ATLANTA, GA - April 16, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc.

GeoVax was using its HHS contract to develop its next-generation multi-antigen COVID-19 vaccine, which is in Phase IIb ...

D. Boral Capital lowered the firm’s price target on GeoVax Labs (GOVX) to $14 from $18 and keeps a Buy rating on the shares.

Despite the PNG award termination, GeoVax anticipates a milestone-rich 2025 across its portfolio. The Company will continue to engage with government and industry partners, pursue clinical trial ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

On April 11, 2025, GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines with a market capitalization of $14.39 million, was instructed to halt all ...

On April 11, 2025, GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing human vaccines with a market capitalization of $14.39 million, was instructed to halt all ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2024 Earnings Call Transcript March 27, 2025 GeoVax Labs, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.79. Operator ...